BioMedWire Stocks

Developing Heart Disease Earlier in Life Increases Cognitive Decline Later in Life

Heart disease is one of the most prolific killers in America, taking one life every 34 seconds and affecting nearly one-half of the country’s population. According to a new study from the University of California, San Francisco, people who develop heart disease earlier in their lives have an increased risk of experiencing cognitive decline later in life.

The study found that people who suffer strokes or heart attacks in middle age may have problems with thinking and memory when they grow older. More specifically, the study focused on individuals who developed heart disease or leg artery disease, or who suffered a stroked before they turned age 60.

Dr. Xiang Jiang, who led the study, and her team analyzed health data from more than 3,100 Americans that was collected for up to 30 years from young adulthood. The study showed that 5% of those in the study developed cardiovascular disease, usually stroke and heart disease, in middle age; these same individuals performed poorly in cognitive tests they took in their 50s.

The researchers found that early cardiovascular disease, usually heart attack, was still associated with worse scores on cognitive tests even when participants with premature stroke were excluded. The research revealed that these individuals tended to perform worse on memory and thinking tests compared to similarly aged people who did not have any cardiovascular diseases. Furthermore, the study found that the patients didn’t have to wait until they were older for these cognitive differences to manifest; they were already discernible before age 60.

Jiang stated that it isn’t exactly clear how these cognitive differences could affect the brain health of people who developed premature cardiovascular disease down the line.

Most studies on the relationship between brain and heart health tend to look at older adults and have generally tied stroke and heart disease to an increased risk of developing cognitive impairment later in life. These cognitive problems can include everything from issues with memory and thinking to full-blown dementia.

Jiang explained that the association between poor heart health and poor brain health could be due to several reasons, including diminished blood flow to the brain. Little is known about the connection between the development of premature cardiovascular disease and the onset of cognitive decline, and Jiang’s study provided much-needed insight.

Still, she stated that this wasn’t definitive proof that premature cardiovascular disease caused cognitive decline, emphasizing that the group’s findings highlighted the need for a heart-healthy lifestyle for people of all ages.

Cognitive decline can have devastating effects on not just the patients but also their families and caregivers. Health monitoring devices commercialized by companies such as MetAlert Inc. (OTC: MLRT) go a long way toward making it easier to take care of someone suffering from dementia and other forms of cognitive decline.

NOTE TO INVESTORS: The latest news and updates relating to MetAlert Inc. (OTC: MLRT) are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…

22 hours ago

Adageis Offering Comprehensive Healthcare AI Tools to Support Profitable Shift to Value-Based Care

Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…

5 days ago

Scientists ID Bacteria That Could Be Behind Multiple Sclerosis Development

A new study focusing on twins has found that individuals with a larger presence of…

5 days ago

How Stem Cells Help in Blood Cancer Treatment

Stem cells are the “master cells” within the body because they can grow into any…

6 days ago

UnitedHealth Records Lower Revenue as Medical Advantage Use Grows

UnitedHealth Group, the largest health insurance firm in the U.S., has reduced its revenue forecast…

1 week ago

Nutriband Inc. (NASDAQ: NTRB): Building a Moat Around Abuse-Deterrent Drug Delivery

Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform AVERSA(TM) Fentanyl targets $80M–$200M…

1 week ago